We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Vitiligo Improvement in a Patient with Ankylosing Spondylitis Treated with Infliximab.
- Authors
Simón, J.-Abraham; Burgos-Vargas, Rubén
- Abstract
Ankylosing spondylitis (AS) is a disabling disease affecting the enthesis and joints of the spine and peripheral sites. Tumour necrosis factor α (TNF-α) is a proinflammatory mediator which plays a significant role in the pathogenesis of AS. Infliximab (a chimeric monoclonal antibody which blocks the activity of TNF-α) is one of the most effective therapies of AS thus far. Vitiligo is a depigmenting disorder of the skin of unknown aetiology affecting 0.5–1% of the population. Here we describe the effect of infliximab on vitiligo in a patient with AS. Copyright © 2008 S. Karger AG, Basel
- Publication
Dermatology (10188665), 2008, Vol 216, Issue 3, p234
- ISSN
1018-8665
- Publication type
Article
- DOI
10.1159/000112932